ZYMAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZYMAR (ZYMAR).
Ofloxacin is a fluoroquinolone antibacterial that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
| Metabolism | Not extensively metabolized; less than 10% excreted in urine as unchanged drug following ophthalmic administration. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of an administered dose; biliary/fecal excretion accounts for about 30%. |
| Half-life | Terminal elimination half-life is approximately 4.5 hours in adults, supporting twice-daily dosing for ocular infections. |
| Protein binding | Approximately 50% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Ophthalmic: systemic bioavailability is minimal (less than 5%) following topical ocular administration. |
| Onset of Action | Topical ophthalmic: clinical effect observed within 1 hour following instillation. |
| Duration of Action | Duration of action is approximately 12 hours, correlating with the dosing interval of every 12 hours for ophthalmic use. |
| Molecular Weight | 370.36 |
1 drop instilled into the affected eye(s) every 2 hours while awake on Day 1, then 1 drop 4 times daily on Days 2 through 7.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment; systemically absorbed drug is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment; systemically absorbed drug is minimal. |
| Pediatric use | Children ≥1 year: same as adult dosing; safety and efficacy in infants <1 year not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. |
| 1st trimester | No adequate studies in pregnant women; use only if potential benefit justifies risk to fetus. |
| 2nd trimester | No adequate studies in pregnant women; use only if potential benefit justifies risk to fetus. |
| 3rd trimester | Avoid use near term due to theoretical risk of premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for ZYMAR (ZYMAR).
| Placental transfer | Limited data; as a topical ophthalmic agent, systemic absorption is minimal, and placental transfer is likely negligible. |
| Breastfeeding | Systemic absorption after topical ocular use is low; however, caution is advised as NSAIDs may accumulate in breast milk. Not expected to cause adverse effects in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None for ophthalmic use. Systemic fluoroquinolones have black box warnings for tendinitis/tendon rupture, peripheral neuropathy, and CNS effects, but these are not applicable to topical ophthalmic formulations.
| Serious Effects |
Hypersensitivity to gatifloxacin or any component of the formulationHistory of tendinitis or tendon rupture with fluoroquinolone use
| Precautions | Prolonged use may result in overgrowth of nonsusceptible organisms including fungi., Do not inject subconjunctivally or introduce into the anterior chamber of the eye., Patients should not wear contact lenses during treatment., Avoid contamination of the dropper tip. |
| Food/Dietary | No specific food interactions are known for ophthalmic gatifloxacin. Systemic absorption is minimal, so dietary restrictions do not apply. |
Loading safety data…
| L2 (Possibly Compatible) |
| Teratogenic Risk | ZYMAR (gatifloxacin ophthalmic solution) is pregnancy category C. Systemic exposure is minimal after ocular administration, but no well-controlled studies in pregnant women. In animal studies, gatifloxacin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (approximately 2000 times the maximum recommended human ophthalmic dose). However, due to potential risk, use during pregnancy only if clearly needed. First trimester: No known fetal risk; second and third trimester: no known risk. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required for ophthalmic use. Standard monitoring for any medication applied during pregnancy applies. |
| Fertility Effects | No studies have assessed the effect of gatifloxacin ophthalmic solution on fertility. Systemic fluoroquinolones have been associated with reproductive toxicity in animal studies at high doses, but relevance to ophthalmic use is negligible due to minimal systemic absorption. |
| Clinical Pearls | ZYMAR (gatifloxacin ophthalmic solution) is a fourth-generation fluoroquinolone antibiotic used for bacterial conjunctivitis. It has enhanced activity against Gram-positive organisms, including Streptococcus pneumoniae, and retains good Gram-negative coverage. Administer one drop every 2 hours while awake on days 1-2, then four times daily on days 3-7. Avoid use in patients with known fluoroquinolone hypersensitivity. Monitor for signs of corneal perforation in patients with corneal epithelial defects. |
| Patient Advice | Wash hands before and after each use to prevent contamination. · Do not touch the dropper tip to any surface, including the eye. · Insert one drop into the affected eye(s) as prescribed; blink gently to distribute. · Wait at least 5 minutes between applying other eye drops. · Avoid wearing contact lenses during treatment unless advised otherwise. · Complete the full course even if symptoms improve to prevent resistance. · Report any signs of allergic reaction, such as rash or swelling, to your healthcare provider. |